| Cat. No. |
Product Name |
Information |
| PC-20878 |
BI-2493
|
BI-2493 is a structural analogue of BI-2865 for in vivo administration, BI-2493 a potent, inactive state selective, non-covalent pan KRAS inhibitor. |
| PC-20877 |
BI-2865
|
BI-2865 is a potent, inactive state selective, non-covalent pan KRAS inhibitor, binds to the GDP-loaded state of WT, G12C, G12D, G12V and G13D KRAS with high affinity (ITC Kd values,10-40 nM), inactivates common cancer-causing KRAS mutants. |
| PC-20608 |
RMC-6291
|
RMC-6291 (RMC6291) is a potent, covalent, next-generation, mutant-selective inhibitor of active state KRAS G12C(ON) with IC50 of 0.7 nM (pERK), RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). |
| PC-49406 |
BI-0474
|
BI-0474 (BI 0474) is a potent, in vivo active KRAS G12C inhibitor with IC50 of 7.0 nM in GDP-KRAS::SOS1 protein-protein interaction assay. |
| PC-38549 |
AZD4625
|
AZD4625 is a potent, selective, covalent allosteric inhibitor of mutant GTPase KRAS G12C with IC50 of 3 nM, inhibitor H358 cell proliferation with GI50 of 4 nM. |
| PC-38438 |
MRTX-EX185
|
MRTX-EX185 (EX185) is a novel potent small-molecule inhibitor of KRAS mutants, exhibits target engagement against KRAS(G12D) with IC50 of 90 nM, binds to GDP-loaded KRAS and KRAS(G12D), as well as the active GNP state. |
| PC-73419 |
Garsorasib
|
Garsorasib (D-1553) is a potent, selective, orally bioavailable and covalent KRas-G12C inhibitor with IC50 of 10 nM, exhibits potent anti-tumor activity in a broad spectrum of tumor cell lines. |
